Clinical

Consensus statements for management of Barrett's dysplasia and early-stage oesophageal adenocarcinoma

NICE has accredited the process used by the BAD CAT (BArrett's Dysplasia and CAncer Taskforce) consensus group to produce its guidelines using consensus statements for management of Barrett's dysplasia and early-stage oesophageal adenocarcinoma. Accreditation is valid for 5 years from September 2012 and is retrospectively applicable to guidance produced using the processes described in the International consensus of the management of dysplastic Barrett's and cancer (2010).